Immunity to Bordetella pertussis

Microbes and Infection

Volumn 3, Issue 8, 2001, Pages 655-677

  Mills, Kingston H G ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Bordetella pertussis; Immune subversion; Immunological memory; Neurological response; Pertussis vaccine; Protective immunity; Th1; Th2; Tr1 cell

Indexed keywords

ADENYLATE CYCLASE TOXIN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; CYTOTOXIN; ENDOTOXIN; HEAT LABILE TOXIN; HEMAGGLUTININ; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

BACTERIAL INFECTION; BORDETELLA PERTUSSIS; CELL INFILTRATION; CELL PROTECTION; CELL TYPE; CELLULAR IMMUNITY; CLINICAL TRIAL; FIMBRIA; FUNCTIONAL ASSESSMENT; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION PREVENTION; LUNG INFECTION; LYMPH NODE; NONHUMAN; PASSIVE IMMUNIZATION; PERTUSSIS; PRIORITY JOURNAL; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SURVIVAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; ULCEROGENESIS; VACCINATION;

BACTERIA (MICROORGANISMS); BORDETELLA PERTUSSIS;

EID: 0034974006     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(01)01421-6     Document Type: Review

References (189)

1. Pertussis: A worldwide problem
2. Report of the task force on pertussis immunization - 1988
3. Pertussis deaths: Report of 23 cases in the United States, 1992 and 1993
4. Evidence of whooping-cough-vaccine efficacy from the 1978 whooping-cough epidemic in Hertfordshire
5. Efficacy of pertussis vaccination in England. Report from the PHLS Epidemiological Research Laboratory and 21 area health authorities
6. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal
7. Pertussis immunisation and serious acute neurological illness in children
8. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines
9. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis
10. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine
11. A placebo-controlled trial of a pertussis-toxoid vaccine
12. Pertussis vaccine
13. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis
14. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses
15. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis
16. Detection of Bordetella pertussis associated with the alveolar macrophages of children with human immunodeficiency virus infection
17. Integrin mediated localization of Bordetella pertussis within human macrophages: Role in pulmonary colonization
18. Bordetella pertussis induces respiratory burst activity in human polymorphonuclear leukocytes
19. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity
20. + T cells for key functions other than specific antibody production
21. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis
22. Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of IFN-γ receptor or immunoglobulin μ chain genes
23. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines
24. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children
25. Time-course of infection and responses in a coughing rat model of pertussis
26. Responses to acellular pertussis vaccines and component antigens in a coughing-rat model of pertussis
27. Vaccination against whooping cough: Relation between protection in children and results of laboratory tests
28. A consideration of control requirements for acellular pertussis vaccines
29. Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: Variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0
30. Development of a nitric oxide induction assay as a potential replacement for the intracerebral mouse protection test for potency assay of pertussis whole cell vaccines
31. Effect of pertussis toxin on the induction of nitric oxide synthesis in murine macrophages and on protection in vivo
32. IFN-γ-mediated protection against intracerebral challenge with Bordetella pertussis in mice
33. Bordetella pertussis respiratory tract infection in the mouse: Pathophysiological responses
34. Aerosol infection of mice with Bordetella pertussis
35. Induction of inflammatory cytokines in the brain following respiratory infection with Bordetella pertussis
36. A respiratory challenge model for infection with Bordetella pertussis: Application in the assessment of pertussis vaccine potency and in defining the mechanism of protective immunity
37. Role of gamma interferon in natural clearance of Bordetella pertussis infection
38. Lethal infection by Bordetella pertussis mutants in the infant mouse model
39. An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines
40. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines
41. Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model
42. Specific immunoglobulin for treatment of whooping cough
43. Pertussis vaccines - Old and new
44. Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis
45. Construction and characterization in vivo of Bordetella pertussis aroA mutants
46. Mechanism of pertussis toxin B oligomer-mediated protection against Bordetella pertussis respiratory infection
47. Cell-mediated immunity to Bordetella pertussis: Role of Th1 cells in bacterial clearance in a murine respiratory infection model
48. Rabbit nasopharyngeal colonization by Bordetella pertussis: The effects of immunization on clearance and on serum and nasal antibody levels
49. Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis
50. Bordetella pertussisinfection in mice: Correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system
51. Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice
52. Organogenic role of B lymphocytes in mucosal immunity
53. Standardization of acellular pertussis vaccine by assay of serum neutralizing antibodies to pertussis toxin (antitoxin): Analogy with diphtheria toxoid
54. A randomized clinical trial of acellular pertussis vaccines in healthy adults: Dose-response comparisons of 5 vaccines and implications for booster immunization
55. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis
56. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines
57. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells
58. Rational design of vaccines
59. The role of the S-1 and B-oligomer components of pertussis toxin in its adjuvant properties for Th1 and Th2 cells
60. Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines
61. Isotype and antigen specificity of pertussis agglutinins following whole-cell pertussis vaccination and infection with Bordetella pertussis
62. Role of Bordetella pertussis virulence factors in adherence to epithelial cell lines derived from the human respiratory tract
63. Role of the Bordetella pertussis P.69/pertactin protein and the P.69/pertactin RGD motif in the adherence to and invasion of mammalian cells
64. Role of carbohydrate recognition domains of pertussis toxin in adherence of Bordetella pertussis to human macrophages
65. The filamentous haemagglutinin, a multifaceted adhesion produced by virulent Bordetella spp
66. A novel adherence assay for Bordetella pertussis using tracheal organ cultures
67. Characterization of antibody inhibiting adherence of Bordetella pertussis to human respiratory epithelial cells
68. Effect of monoclonal antibodies on the adherence of Bordetella pertussis to Vero cells
69. An assay of Bordetella pertussis adhesion to tissue-culture cells
70. Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells
71. Uptake and intracellular survival of Bordetella pertussis in human macrophages
72. Role of adhesins and toxins in invasion of human tracheal epithelial cells by Bordetella pertussis
73. Bordetella pertussis virulence factors affect phagocytosis by human neutrophils
74. Evidence for an intracellular niche for Bordetella pertussis in broncho-alveolar lavage cells of mice
75. Virulence factors determine attachment and ingestion of nonopsonized and opsonized Bordetella pertussis by human monocytes
76. Macrophage behaviour during the complaisant phase of murine pertussis
77. Phagocytosed Bordetella pertussis fails to survive in human neutrophils
78. Intracellular survival of virulent Bordetella pertussis in human polymorphonuclear leukocytes
79. The adenylate cyclase toxin contributes to the survival of Bordetella pertussis within human macrophages
80. Inhibition of lymphocyte and neutrophil chemotaxis by pertussis toxin
81. Bordetella pertussisadenylate cyclase toxin: Intoxication of host cells by bacterial invasion
82. Cloning and sequencing of a Bordetella pertussis serum resistance locus
83. Serum resistance in bvg-regulated mutants of Bordetella pertussis
84. Pregenomic comparative analysis between Bordetella bronchiseptica RB50 and Bordetella pertussis tohama I in murine models of respiratory tract infection
85. A bactericidal monoclonal antibody specific for the lipooligosaccharide of Bordetella pertussis reduces colonization of the respiratory tract of mice after aerosol infection with B. pertussis
86. Analysis of protective and nonprotective monoclonal antibodies specific for Bordetella pertussis lipooligosaccharide
87. Characterization of human bactericidal antibodies to Bordetella pertussis
88. Enzyme-linked immunosorbent assay for detection of pertussis immunoglobulin A in nasopharyngeal secretions as an indicator of recent infection
89. Antibody responses in the serum and respiratory tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid
90. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA
91. Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit
92. Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection
93. Bordetella pertussis filamentous hemagglutinin enhances the immunogenicity of liposome-delivered antigen administered intranasally
94. Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis
95. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: Effects of formaldehyde treatment
96. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells
97. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles
98. Pertussis in a previously immunized child with human immunodeficiency virus infection
99. Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT- 9K/129G
100. Identification of subregions of Bordetella pertussis filamentous hemagglutinin that stimulate human T-cell responses
101. Dissecting human T cell responses against Bordetella species
102. Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones against Bordetella pertussis
103. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells
104. Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussisin the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults
105. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines
106. Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens
107. The cellular immune response to Bordetella pertussis in two children with whooping cough
108. Cell-mediated immune responses to antigens of Bordetella pertussis and protection against pertussis in school children
109. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine
110. Bordetella pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine: Comparison of the T cell cytokine profiles in infants and mice
111. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE against pertussis toxin but not against common allergens
112. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine
113. Proliferative responses and gamma interferon and tumor necrosis factor production by lymphocytes isolated from tracheobroncheal lymph nodes and spleen of mice aerosol infected with Bordetella pertussis
114. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: Implications for long-term immunity in children
115. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: Adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28
116. Mechanisms of immunity to the respiratory pathogen Bordetella pertussis in normal and gene knockout mice: Clearance of primary infection is not enhanced by therapeutic interleukin-12
117. Effects of recombinant human gamma interferon on intracellular survival of Bordetella pertussis in human phagocytic cells
118. Unexpected isolation of Bordetella pertussis from a blood culture
119. Interferon-γ mediated immune effector mechanisms against Bordetella pertussis
120. Compartmentalization of T cell responses following respiratory infection with Bordetella pertussis: Hyporesponsiveness of lung T cells is associated with modulated expression of the co-stimulatory molecule CD28
121. Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins
122. Dendritic cells are recruited into the airway epithelium during the inflammatory response to a broad spectrum of stimuli
123. Role of adenylate cyclase-hemolysin in alveolar macrophage apoptosis during Bordetella pertussis infection in vivo
124. Pertussis toxin from Bordetella pertussis blocks neutrophil migration and neutrophil-dependent edema in response to inflammation
125. Gamma delta T cells are decreased in the blood of children with Bordetella pertussis infection
126. A regulatory role for IL-4 in differential inflammatory responses in the lung following infection of mice primed with Th1- or Th2-inducing pertussis vaccines
127. Direct anti-inflammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis
128. Interferon-gamma levels in serum and bronchoalveolar lavage fluid of mice infected with Bordetella pertussis
129. In vitro and in vivo induction of nitric oxide by murine macrophages stimulated with Bordetella pertussis
130. Nitric oxide induction by pertussis toxin in mouse spleen cells via gamma interferon
131. Fluorescent labels influence phagocytosis of Bordetella pertussis by human neutrophils
132. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: Temporal trends and evidence for vaccine-driven evolution
133. Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine
134. Vaccination with pertussis toxin alters the antibody response to simultaneous respiratory syncytial virus challenge
135. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine
136. Give us this day our daily germs
137. Contribution of regulation by the bvg locus to respiratory infection of mice by Bordetella pertussis
138. Adenylate cyclase toxin is critical for colonization and pertussis toxin is critical for lethal infection by Bordetella pertussis in infant mice
139. Construction and characterization of Bordetella pertussis mutants lacking the vir-regulated P.69 outer membrane protein
140. Targeted mutations that ablate either the adenylate cyclase or hemolysin function of the bifunctional cyaA toxin of Bordetella pertussis abolish virulence
141. Role of the Bordetella pertussis minor fimbrial subunit, FimD, in colonization of the mouse respiratory tract
142. Filamentous hemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonization
143. Bordetella pertussis hemagglutinin interacts with a leukocyte signal transduction complex and stimulates bacterial adherence to monocyte CR3 (CD11b/CD18)
144. Filamentous, haemagglutinin and pertussis toxin from Bordetella pertussis modulate immune responses to unrelated antigens
145. Bordetella pertussis infection of human monocytes inhibits antigen-dependent CD4 T cell proliferation
146. Pertussis toxin has eukaryotic-like carbohydrate recognition domains
147. Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin
148. Perspectives in recombinant pertussis toxoid development
149. Pertussis toxin pretreatment alters the in vivo cell division behaviour and survival of B lymphocytes after intravenous transfer
150. Altered mononuclear phagocyte function in mice treated with the lymphocytosis promoting factor of Bordetella pertussis
151. Effect of hyperreactivity to endotoxin on the toxicity of pertussis vaccine and pertussis toxin in mice
152. + T lymphocytes
153. 2+ signaling in human neutrophil granulocytes
154. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3
155. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis
156. Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone
157. Enhancement of interleukin-4 production by pertussis toxin
158. Regulation of DTH and IgE responses by IL-4 and IFN-gamma in immunized mice given pertussis toxin
159. Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule
160. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children
161. Enhancing effects of pertussis toxin B oligomer on the immunogenicity of influenza vaccine administered intranasally
162. Co-stimulation of T cells via CD28 inhibits human IgE production; reversal by pertussis toxin
163. Pertussis toxin interferes with superantigen-induced deletion of peripheral T cells without affecting T cell activation in vivo. Inhibition of deletion and associated programmed cell death depends on ADP-ribosyltransferase
164. Pertussis toxin prevents the induction of peripheral T cell anergy and enhances the T cell response to an encephalitogenic peptide of myelin basic protein
165. Immunomodulation of murine experimental autoimmune encephalomyelitis by pertussis toxin: The protective activity, but not the disease-enhancing activity, can be attributed to the nontoxic B-oligomer
166. Inhibition of monocyte oxidative responses by Bordetella pertussis adenylate cyclase toxin
167. Adaptive responses of human monocytes infected by Bordetella pertussis: The role of adenylate cyclase hemolysin
168. The role of the O antigen in adjuvant activity of lipopolysaccharide
169. Bordetella pertussis tracheal cytotoxin and other muramyl peptides: Distinct structure-activity relationships for respiratory epithelial cytopathology
170. Interleukin-1 is linked to the respiratory epithelial cytopathology of pertussis
171. Effects of Bordetella pertussis infection on human respiratory epithelium in vivo and in vitro
172. Epithelial autotoxicity of nitric oxide: Role in the respiratory cytopathology of pertussis
173. Effect of tracheal cytotoxin from Bordetella pertussis on human neutrophil function in vitro
174. Regulation of inflammatory responses to Bordetella pertussis by N(G)-monomethyl-L-arginine in mice intranasally infected
175. Bordetella pertussis fimbriae bind to human monocytes via the minor fimbrial subunit FimD
176. Binding of FimD on Bordetella pertussis to very late antigen-5 on monocytes activates complement receptor type 3 via protein tyrosine kinases
177. Local transient induction of inflammatory cytokines after intranasal administration of recombinant Bordetella pertussis
178. Acute encephalopathy and chronic neurological damage after pertussis vaccine
179. Pertussis toxin is required for pertussis vaccine encephalopathy
180. The activity of purified Bordetella pertussis components in murine encephalopathy
181. Anaphylaxis or so-called encephalopathy in mice sensitized to an antigen with the aid of pertussigen (pertussis toxin)
182. Pro-inflammatory cytokines in the adverse systemic and neurologic effects associated with parenteral injection of a whole cell pertussis vaccine
183. Whole cell but not acellular pertussis vaccines induce convulsive activity in mice: Evidence of a role for IL-1β in a new murine model for neuronal side effects of vaccination
184. Interlukin-1β-dependant changes in the hippocampus following parenteral immunization with a whole cell pertussis vaccine
185. Pertussis encephalopathy with high cerebrospinal fluid antibody titers to pertussis toxin and filamentous hemagglutinin
186. Enhancement of histamine-induced vascular leakage by pertussis toxin in SJL/J mice but not BALB/c mice
187. Reversible opening of the blood-brain barrier by anti-bacterial antibodies
188. Nitric oxide induction in murine macrophages and spleen cells by whole-cell Bordetella pertussis vaccine
189. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines